Cognition Therapeutics’ (CGTX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Cognition Therapeutics (NASDAQ:CGTX) in a research report released on Monday morning, Benzinga reports. HC Wainwright currently has a $5.00 target price on the stock.

CGTX has been the topic of several other reports. B. Riley reissued a “neutral” rating and set a $1.00 target price (down from $5.00) on shares of Cognition Therapeutics in a research note on Tuesday, August 6th. Cantor Fitzgerald lowered shares of Cognition Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, July 30th. Finally, Chardan Capital restated a “buy” rating and issued a $11.00 target price on shares of Cognition Therapeutics in a research note on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Cognition Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Cognition Therapeutics Price Performance

Shares of Cognition Therapeutics stock opened at $0.50 on Monday. The stock’s 50-day moving average is $0.52 and its 200 day moving average is $1.27. Cognition Therapeutics has a one year low of $0.34 and a one year high of $2.95. The firm has a market cap of $20.06 million, a price-to-earnings ratio of -0.53 and a beta of 1.34.

Cognition Therapeutics (NASDAQ:CGTX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. During the same period in the prior year, the firm earned ($0.16) EPS. On average, sell-side analysts expect that Cognition Therapeutics will post -0.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Cognition Therapeutics

Several large investors have recently added to or reduced their stakes in CGTX. Hohimer Wealth Management LLC purchased a new stake in shares of Cognition Therapeutics in the first quarter worth approximately $410,000. Tocqueville Asset Management L.P. purchased a new stake in Cognition Therapeutics in the 1st quarter valued at $47,000. CM Management LLC bought a new position in Cognition Therapeutics during the 1st quarter valued at $318,000. AWM Investment Company Inc. purchased a new position in Cognition Therapeutics during the 1st quarter worth $1,183,000. Finally, Levin Capital Strategies L.P. bought a new stake in shares of Cognition Therapeutics in the 1st quarter worth $55,000. Institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.